These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 23116346)

  • 21. Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors.
    Artini PG; Ruggiero M; Monteleone P; Carpi A; Cristello F; Cela V; Genazzani AR
    Biomed Pharmacother; 2008; 62(6):373-7. PubMed ID: 18037256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Study on serum vascular endothelial growth factor level in ovarian malignant tumors].
    Li L; Wang LM; Zhang W; Zhang JQ; Song HL; Yao DS; Tang Y; Chen XQ; Yang ZH
    Zhonghua Fu Chan Ke Za Zhi; 2003 Feb; 38(2):72-6. PubMed ID: 12783691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Histopathologic prognostic factors, serum markers and selected molecular biologic factors in ovarian carcinoma].
    Spacek J; Jílek P; Petera J; Tesarík Z
    Ceska Gynekol; 2002 Nov; 67(6):343-9. PubMed ID: 12661373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Studies on angiogenesis in the benign and malignant ovarian neoplasms with the use of color and pulsed Doppler sonography and serum CA-125, CA-19.9, CA-72.4 and vascular endothelial growth factor measurements.
    Czekierdowski A
    Ann Univ Mariae Curie Sklodowska Med; 2002; 57(1):113-31. PubMed ID: 12898913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A new opportunity in ovarian cancer treatment].
    Sedláková I
    Ceska Gynekol; 2012 Oct; 77(5):469-71. PubMed ID: 23116353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Significance of vascular endothelial growth factor expression in serum of patients with hepatocellular carcinoma].
    Zhao J; Hu J; Cai J
    Zhonghua Zhong Liu Za Zhi; 2001 Sep; 23(5):389-92. PubMed ID: 11810769
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Serum level and expression of vascular epithelial growth factor in ovarian epithelial carcinoma].
    Sun LX; Wu Y; Han HQ; Wang QH
    Ai Zheng; 2003 Jan; 22(1):58-61. PubMed ID: 12561438
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 are highly expressed in ovarian granulosa cell tumors.
    Färkkilä A; Anttonen M; Pociuviene J; Leminen A; Butzow R; Heikinheimo M; Unkila-Kallio L
    Eur J Endocrinol; 2011 Jan; 164(1):115-22. PubMed ID: 21041381
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vascular endothelial growth factor expression in serum of patients with hepatocellular carcinoma.
    Zhao J; Hu J; Cai J; Yang X; Yang Z
    Chin Med J (Engl); 2003 May; 116(5):772-6. PubMed ID: 12875699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elevated vascular endothelial growth factor pretreatment levels are correlated with the tumor burden in Hodgkin lymphoma and continue to be elevated in prolonged complete remission.
    Rueda A; Olmos D; Villareal V; Torres E; Pajares BI; Alba E
    Clin Lymphoma Myeloma; 2007 May; 7(6):400-5. PubMed ID: 17621405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lysophosphatidic acid: an ovarian cancer marker.
    Sedláková I; Vávrová J; Tosner J; Hanousek L
    Eur J Gynaecol Oncol; 2008; 29(5):511-4. PubMed ID: 19051824
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic relevance of serum vascular endothelial growth factor in ovarian cancer.
    Oehler MK; Caffier H
    Anticancer Res; 2000; 20(6D):5109-12. PubMed ID: 11326678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The VEGF and BMP-2 levels in patients with ankylosing spondylitis and the relationship to treatment with tumour necrosis factor alpha inhibitors.
    Tošovský M; Bradna P; Andrýs C; Andrýsová K; Cermáková E; Soukup T
    Acta Medica (Hradec Kralove); 2014; 57(2):56-61. PubMed ID: 25257151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
    Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
    Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Primary drug resistance/sensitivity in vitro and clininical outcome in ovarian cancer patients].
    Sedláková I; Tosner J; Cervinka M; Brigulová K; Rezác A; Spacek J; Laco J; Skapinec P
    Ceska Gynekol; 2011 Jun; 76(3):184-9. PubMed ID: 21838147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic value of serum VEGF in women with ovarian tumors.
    Oehler MK; Caffier H
    Anticancer Res; 1999; 19(4A):2519-22. PubMed ID: 10470186
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiogenic protein expression in advanced epithelial ovarian cancer.
    Barton DP; Cai A; Wendt K; Young M; Gamero A; De Cesare S
    Clin Cancer Res; 1997 Sep; 3(9):1579-86. PubMed ID: 9815846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum sFas, leptin, and VEGF in patients with ovarian cancer and benign tumors.
    Vysotskii MM; Digaeva MA; Kushlinskii NE; Abbasova SG; Laktionov KP; Ermilova VD; Bakhoeva KA; Kryuk YV; Manukhin IB
    Bull Exp Biol Med; 2009 Nov; 148(5):810-4. PubMed ID: 20396799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Resistance/sensitivity in vitro in ovarian cancer patients].
    Sedláková I; Tosner J; Rezác A; Cervinka M; Brigulová K; Spacek J; Tomsová M; Skapinec P
    Ceska Gynekol; 2010 May; 75(3):182-7. PubMed ID: 20731297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of ovarian cancer biomarkers in subjects with benign asbestos-related pleural diseases.
    Park EK; Johnson AR; Yates DH; Thomas PS
    Clin Chem Lab Med; 2011 Jan; 49(1):147-50. PubMed ID: 20961188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.